Israel Englander Akebia Therapeutics, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 45,685 shares of AKBA stock, worth $62,131. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,685

Previous 3,266,000 98.6%

Holding current value

$62,131

Previous $5.98 Million 99.23%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $2.77 Million - $5.25 Million	-3,220,315 Reduced 98.6%	45,685 $46,000
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $845,836 - $1.49 Million	666,013 Added 25.62%	3,266,000 $5.98 Million
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $475,223 - $760,357	594,029 Added 29.61%	2,599,987 $3.22 Million
Q2 2023 Aug 14, 2023	BUY	$0.51 - $1.43 $558,450 - $1.57 Million	1,095,000 Added 120.2%	2,005,958 $1.85 Million
Q1 2023 May 15, 2023	SELL	$0.56 - $1.15 $241,619 - $496,183	-431,464 Reduced 32.14%	910,958 $511,000
Q4 2022 Feb 14, 2023	SELL	$0.25 - $0.58 $534,609 - $1.24 Million	-2,138,436 Reduced 61.43%	1,342,422 $775,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $561,995 - $861,725	-1,873,317 Reduced 34.99%	3,480,858 $1.1 Million
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.67 $871,155 - $1.82 Million	2,722,361 Added 103.44%	5,354,175 $1.89 Million
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $509,745 - $2.07 Million	707,980 Added 36.8%	2,631,814 $1.89 Million
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $4.35 Million - $6.43 Million	1,923,834 New	1,923,834 $4.35 Million
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $622,641 - $1.03 Million	-264,954 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $3.07 Million - $4.55 Million	-1,083,339 Reduced 80.35%	264,954 $1 Million
Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $1.75 Million - $3.03 Million	-598,214 Reduced 30.73%	1,348,293 $4.56 Million
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $578,911 - $985,714	-260,771 Reduced 11.81%	1,946,507 $5.45 Million
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $5.28 Million - $28.9 Million	2,207,278 New	2,207,278 $5.54 Million
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $5.74 Million - $11.7 Million	-860,215 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$4.1 - $10.24 $775,543 - $1.94 Million	189,157 Added 28.19%	860,215 $6.52 Million
Q4 2019 Feb 14, 2020	BUY	$3.16 - $6.73 $1.97 Million - $4.19 Million	622,424 Added 1279.81%	671,058 $4.24 Million
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $452,628 - $688,505	-127,501 Reduced 72.39%	48,634 $190,000
Q2 2019 Aug 15, 2019	SELL	$4.1 - $8.05 $767,060 - $1.51 Million	-187,088 Reduced 51.51%	176,135 $852,000
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $1.35 Million - $2.64 Million	328,298 Added 940.01%	363,223 $3.79 Million
Q1 2019 May 14, 2019	SELL	$5.41 - $8.73 $1.1 Million - $1.77 Million	-202,602 Reduced 85.3%	34,925 $286,000
Q4 2018 Feb 14, 2019	SELL	$5.39 - $9.15 $107,395 - $182,313	-19,925 Reduced 7.74%	237,527 $1.31 Million
Q3 2018 Nov 14, 2018	SELL	$7.44 - $10.65 $993,373 - $1.42 Million	-133,518 Reduced 34.15%	257,452 $2.27 Million
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $2.44 Million - $3.03 Million	-267,052 Reduced 40.58%	390,970 $3.9 Million
Q1 2018 May 15, 2018	SELL	$9.53 - $15.68 $3.49 Million - $5.75 Million	-366,470 Reduced 35.77%	658,022 $6.27 Million
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $3.43 Million - $4.72 Million	240,692 Added 30.71%	1,024,492 $15.2 Million
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $10.2 Million - $15.4 Million	783,800	783,800 $15.4 Million

Others Institutions Holding AKBA

# of Institutions

110

Shares Held

55.3M

Call Options Held

554K

Put Options Held

246K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $250M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account